#AI Drug Discovery

Demis Hassabis: Two Labs, Three Titles, and a $3.5B Drug Bet

Demis Hassabis now holds three formal roles inside Alphabet: Chairman of Google DeepMind, CEO of Isomorphic Labs, and the company's first Chief Scientist. StartupHub.ai data shows DeepMind employs 8,831 people with $1.33 billion in annual revenue, while Isomorphic Labs closed a $2.1 billion Series B in May 2026, carries a $3.5 billion valuation, and has $3 billion in combined pharmaceutical partnership ceilings with Eli Lilly and Novartis.

Architectural Interactivity, Linguistic Interpretability, and Molecular Synthesis: The Frontier of Native AI

Three organisations now define the frontier of native AI: Thinking Machines is rebuilding human-AI collaboration as a low-latency interaction model, the Effable movement wants interpretable safety frameworks like SafetyAnalyst, and Isomorphic Labs is converting AlphaFold into an end-to-end drug design engine. The common thread is moving from AI as a layer of abstraction toward AI as a fundamental component of human and biological systems.

Demis Hassabis in 2026: How DeepMind Is Turning AlphaFold Into a Drug Discovery Engine

Demis Hassabis has spent 2026 arguing that AlphaFold is the first rung in an AI-powered scientific revolution. Here is how his thesis maps to Isomorphic Labs' drug pipeline, DeepMind's research agenda, and his view that the generative AI boom may paradoxically slow deeper progress.

AbbVie's AI Strategy: Reshaping Pharma from Discovery to Patient Impact

CNBC Disruptor 50 on Formation Bio to Redefine Drug Development

Kiin Bio Secures €1.9 Million Pre-Seed Funding for AI-Powered Drug Discovery Platform

London-based life sciences startup Kiin Bio has successfully raised €1.9 million in an oversubscribed pre-Seed funding round.

Kiin Bio Secures €1.9 Million Pre-Seed Funding for AI-Powered Drug Discovery Platform

London-based life sciences startup Kiin Bio has successfully raised €1.9 million in an oversubscribed pre-Seed funding round.